Investor Presentation First Nine Months of 2023
9
Investor presentation
First nine months of 2023
Novo NordiskⓇ
Obesity care sales grew by 174% in the first nine months of 2023
mainly driven by the US
NN sales and volume BAOM market growth
within Obesity care
Branded AOM TRX in the US²
DKK billion
55%¹
15
TRX count ('000s)
84%1
174%1
180
94%
95%
160
ONCE-WEEKLY
wegovy
semaglutide injection 2.4 mg
The US
12
140
75%
120
9
109
55%
100
•
Commercial relaunch in January 2023
•
Broad commercial formulary access
While supply capacity is gradually
98
80
16
35%
60
40
3
15%
20
0
-5%
0
2021
2022
2023
June
2021
IO INAO
-
- BAOM Market growth (RHS)
SaxendaⓇ
3
October
2023
Volume capped launches in IO in
2023, balancing supply and demand
-WegovyⓇ
being expanded, the supply of the
lower dose strengths will remain
restricted to safeguard continuity of
care
International Operations
WegovyⓇ launched in Denmark,
Norway, Germany, UK and Iceland
NN sales growth at CER
¹Annual growth at CER. Each TRX data points represents one week of data; 2IQVIA weekly, 20 October 2023
Branded AOM market
NAO: North America operations; IO: International operations; RHS: Right-hand side axis; TRX: Total Prescriptions; AOM: Anti-Obesity Medications (includes WegovyⓇ, SaxendaⓇ, Qsymia, Belviq and Contrave); BAOM: Branded AOM market; CER: Constant exchange
Note: Sales growth at constant exchange rates. 94% volume growth for Global BAOM market growth refers to moving annual total.
ratesView entire presentation